Ibrahim Malami

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 9

Top Venues

Natural product research

The British journal of nutrition

Drug and chemical toxicology

Epigenomics

Usmanu Danfodiyo University Faculty of Pharmaceutical Science

Universiti Putra Malaysia (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Usmanu Danfodiyo University Faculty of Pharmaceutical Science

Nigeria

Lecturer and Researcher :: Pharmacognosy and Ethnopharmacy

Education History

Universiti Putra Malaysia - Feb 6o 2017

Malaysia

PHD :: Institute of Bioscience

Publications

Ibrahim Malami, Alhassan Alhassan, Adamu Adamu, Muhammad Bello, Aliyu Muhammad, Mustapha Imam
Cytotoxic flavokawain B inhibits the growth and metastasis of hepatocellular carcinoma through UCK2 modulation of the STAT3/Hif-1α/VEGF signalling pathway. Current drug targets (2023)
Ibrahim Malami, Muhammad Muhammad Batako, Alhasan Muhammad Alhasan, Ibrahim Babangida Abubakar
Mitracarpus hirtus (L.) DC.: is a potential source for the exploitation of anticancer agents. Natural product research (2022)
Muhammad Aliyu, Gilead Ebiegberi Forcados, Babangida Sanusi Katsayal, Rabiatu Suleiman Bako, Suleiman Aminu, Idris Zubairu Sadiq, Murtala Bello Abubakar, Abdurrahman Pharmacy Yusuf, Ibrahim Malami, Mohammed Faruk, Sani Ibrahim, Peter Abur Pase, Saad A Ahmed, Ibrahim Babangida Abubakar, Murtala Abubakar, Clayton C Yates
Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review. Epigenomics 14 (11) (2022)
Kasimu Ghandi Ibrahim, Dawoud Usman, Muhammad Bashir Bello, Ibrahim Malami, Bilyaminu Abubakar, Murtala Bello Abubakar, Mustapha Umar Imam
Rodent models of metabolic disorders: considerations for use in studies of neonatal programming. The British journal of nutrition (2021)
Alhassan M Alhassan, Qamar Uddin Ahmed, Ibrahim Malami, Zainul Amiruddin Zakaria
Pseudocedrela kotschyi: a review of ethnomedicinal uses, pharmacology and phytochemistry. Pharmaceutical biology 59 (1) (2021)
Ibrahim Malami, Aisha Muktar Bunza, Alhassan Muhammad Alhassan, Muhammad Aliyu, Ibrahim Babangida Abubakar, Abdulmajeed Yunusa, Peter M Waziri, Imaobong C Etti
Dihydroartemisinin as a potential drug candidate for cancer therapy: a structural-based virtual screening for multitarget profiling. Journal of biomolecular structure & dynamics (2020)
Muhammad Aliyu, David Ebuka Arthur, Sanusi Babangida, Ochuko L Erukainure, Ibrahim Malami, Hadiza Sani, Aliyu Waziri Abdulhamid, Idayat Omoyemi Ajiboye, Ahmed Ariyo Saka, Nafisa Muhammed Hamza, Suleiman Asema, Zaharaddeen Muhammad Ado, Taibat Ishaq Musa
Modulatory role of rutin on 2,5-hexanedione-induced chromosomal and DNA damage in rats: validation of computational predictions. Drug and chemical toxicology 43 (2) (2018)
Ibrahim Malami, Aliyu Muhammad, Ibrahim B Abubakar, Imaobong C Etti, Peter M Waziri, Ramadan M Abubakar, Halilu E Mshelia
5,6-dehydrokawain from the rhizome of Alpinia mutica Roxb. induced proangiogenic tumour-derived VEGF of HT-29 colorectal cancer. Natural product research 32 (24) (2017)
Ibrahim Malami, Ahmad Bustamam Abdul, Rasedee Abdullah, Nur Kartinee Bt Kassim, Rozita Rosli, Swee Keong Yeap, Peter Waziri, Imaobong Christopher Etti, Muhammad Bashir Bello
Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells. PloS one 12 (1) (2017)

Ibrahim Malami.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ibrahim Malami